Exelixis is an oncology-focused biotech company innovating cancer treatments for life. Find out how we're dedicated to giving more patients hope for the future.

If you are a healthcare professional and have a question about an Exelixis product, please contact Exelixis Medical Information at [email protected] or call 1-855-292-3935 (EXEL).

Qualified and interested candidates should apply to current openings on our Exelixis Careers website or on LinkedIn, Glassdoor and Indeed. Exelixis accepts no responsibility for any costs …

Exelixis extends its impact through strategic collaborations across drug discovery, development and commercialization, building on our long history of productive partnerships to move our …

* Sairopa B.V. (Sairopa) and Exelixis have an exclusive clinical development and option agreement providing Exelixis the right to acquire ADU-1805. ADC = antibody-drug conjugate; …

Jul 11, 2024 · Exelixis is expanding its global innovation engine to evolve how cancer is treated and deliver for physicians, patients and partners.

Developing new medicines is an iterative process. After testing potential compounds in labs and selecting drug candidates to study further, Exelixis conducts research and clinical trials to …

One of Exelixis’ greatest strengths is its culture of focused execution. We’re committed to moving quickly while turning over every stone to bring new standards of care to physicians and …

As we seek to improve the treatment of patients with cancer, Exelixis is addressing a broad array of targets selected based on rigorous scientific and clinical evidence with the goal of …

Dec 4, 2023 · – STELLAR-305 is Exelixis’ first pivotal study in squamous cell carcinoma of the head and neck – – Trial will evaluate the potential of inhibition of VEGF, MET and AXL, which …